Medicus Pharma director awarded 25,000 stock options

Medicus Pharma Ltd. director Barry Fishman received a grant of stock options covering 25,000 common shares.

Rhea-AI Filing Summary

Medicus Pharma Ltd. director Barry Fishman received a grant of stock options covering 25,000 common shares. The options have an exercise price of $0.50 per share, become exercisable on March 26, 2027, and expire on March 27, 2031. Following this grant, he holds 25,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 25,000 shares

Grant/Award 1 txn

Insider FISHMAN BARRY

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	25,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 25,000 contracts (Direct)

Key Figures

Options granted: 25,000 options Exercise price: $0.50 per share Underlying shares: 25,000 common shares +3 more

6 metrics

Options granted 25,000 options Stock Option (right to buy) grant on March 30, 2026

Exercise price $0.50 per share Conversion or exercise price for 25,000 underlying common shares

Underlying shares 25,000 common shares Shares subject to the stock option grant

Post-transaction derivative holdings 25,000 derivative securities Total stock options following the grant

Exercise start date March 26, 2027 Date options become exercisable

Expiration date March 27, 2031 Date options expire if unexercised

Key Terms

Stock Option (right to buy), Common Shares, Grant, award, or other acquisition

3 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Common Shares financial

"underlying_security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Medicus Pharma (MDCX) report in Barry Fishman’s latest Form 4?

Medicus Pharma reported a stock option grant to director Barry Fishman. He was awarded options for 25,000 common shares, recorded as a derivative acquisition rather than an open-market share purchase, reflecting compensation aligned with future share price performance.

How many Medicus Pharma (MDCX) options were granted to Barry Fishman?

Barry Fishman received stock options on 25,000 underlying common shares. These options increase his derivative exposure to the company, with all 25,000 options shown as held directly following the reported transaction on March 30, 2026.

What is the exercise price of Barry Fishman’s Medicus Pharma (MDCX) options?

The options have an exercise price of $0.50 per common share. This means Fishman can buy up to 25,000 Medicus Pharma common shares at $0.50 each once the options become exercisable, subject to the vesting and expiration terms disclosed.

When do Barry Fishman’s Medicus Pharma (MDCX) options vest and expire?

The options become exercisable on March 26, 2027, and expire March 27, 2031. This creates a multi‑year window during which Fishman may choose to exercise his right to acquire the 25,000 underlying common shares at the fixed $0.50 price.

Did Barry Fishman buy or sell Medicus Pharma (MDCX) shares on the market?

No open-market buys or sells were reported in this Form 4. The filing shows only a compensation-related acquisition coded as a grant of stock options (transaction code A), not a purchase or sale of existing common shares in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/01/2026 - 07:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FISHMAN BARRY

(Last) (First) (Middle)

300 CONSHOHOCKEN STATE ROAD

SUITE 200

(Street)

W. CONSHOHOCKEN PENNSYLVANIA 19428

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Medicus Pharma Ltd. [ MDCX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.5	03/30/2026		A		25,000		03/26/2027	03/27/2031	Common Shares	25,000	$0	25,000	D

Explanation of Responses:

	/s/ Raza Bokhari, as Attorney-in-Fact, for Barry Fishman	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)